ClinicalTrials.gg
RecruitingNCT03860857BEACoNUpdated Jan 23, 2026

Biomarker Exploration in Aging, Cognition and Neurodegeneration

A Phase 3 interventional study of Amyloid PET scan and Tau PET scan using MK-6240 in Alzheimer Disease, Cognitive Impairment and Cognitive Decline, sponsored by University of California, Irvine. Recruiting at 1 site in United States. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by University of California, Irvine · Phase 3, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled May 2018, registered Feb 2019).
  • Started May 2018; still recruiting 8 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,941 studies in Alzheimer Disease with a site in United States — 346 open to participants now, 444 under way, 40 of them phase 3. Alzheimer Disease · United States.

Planned enrollment
311th of 1,610
300 · median 73
Started
2018
with 103 others
Phase 3
188 of 1,941
19 open now
Primary completion
2026-12
later than 100 of 443 live
Registered
1,052nd of 1,941
by date

Among the 1,941 studies in Alzheimer Disease with a site in United States, this one is the 311th largest by planned enrollment of the 1,610 interventional ones that give a count, is one of 104 that started in 2018, is one of 188 in phase 3, reaches primary completion later than 100 of the 443 other live ones, and was the 1,052nd registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

346 of the 1,941 studies in Alzheimer Disease with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,941 studies in Alzheimer Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline. An addendum to this study includes additional PET scans to examine the relationship between tau protein in the brain and cognitive decline. Tau is a protein that is known to form tangles in the areas of the brain important for memory, and these tau tangles are a hallmark of Alzheimer's disease. This sub-study research aims to look at the tau accumulation in the brain using an investigational drug called MK-6240, which is a radio tracer that gets injected prior to a positron emission tomography (PET) scan.

Read the detailed description

This study investigates the relationship between Alzheimer's disease (AD) pathology, brain structure and function, as well as cognition in non-demented older adults. The goal is to develop a more complete understanding of the factors that lead to cognitive decline in the elderly and progression to AD. The investigators will enroll 200 cognitively intact adults between the ages of 60-85 years old from the UCI Alzheimer's Disease Research Center or directly from the local community. Study procedures will include: 1) PET amyloid scans with Amyvid™ radiotracer (florbetapir-F18) and PET tau scans with [18F]MK6240 radiotracer; 2) High-resolution structural, functional, and diffusion MRI; and 3) Cognitive examinations. The investigators will track cognitive outcomes through longitudinal monitoring. Amyloid imaging will only be conducted once in the study at baseline, and MRI and tau PET imaging will be at baseline and Year 1. The investigators aim to identify the best combination of tests for predicting longitudinal cognitive/clinical decline. The proposed study will significantly inform the understanding of cognitive decline in the aging brain and allow investigators to better define preclinical AD and make recommendations for future intervention trials.

03

Conditions studied

  • Alzheimer Disease
  • Cognitive Impairment
  • Cognitive Decline

Keywords

  • Alzheimer disease
  • cognitive impairment
  • mild cognitive impairment
  • biomarker
  • MRI
  • PET
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 60 or older;
  2. Speaks fluent English or Spanish;
  3. Visual and auditory acuity adequate for neuropsychological and computerized testing;
  4. Good general health with no disease(s) expected to interfere with the study;
  5. Willing and able to participate for the duration of the study and in all study procedures including MRI and PET;
  6. Normal cognition defined as a Clinical Dementia Rating of 0 and a score of 25 or higher. FAST Stage 1 or 2.
  7. Subjective memory or other cognitive complaints will be included.

Exclusion criteria

Exclusion Criteria:

  1. Significant co-morbid neurologic disease such as Parkinson's disease, multiple sclerosis, brain cyst, tumor or aneurysm;
  2. Major health conditions, except for Type II diabetes mellitus, hypercholesterolemia, and hypertension, which are NOT exclusionary for this study given their high prevalence in our target populations;
  3. Significant psychiatric disorders such as schizophrenia, bipolar disorder, or attention-deficit hyperactivity disorder, except for depression and anxiety, which are NOT exclusionary for this study given their high prevalence in our target populations;
  4. Existing diagnosis of dementia or mild cognitive impairment;
  5. Alcohol or substance abuse or dependence within the past 2 years ( criteria);
  6. MRI , e.g. pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body. Females who are pregnant or trying to get pregnant are also excluded;
  7. PET contraindications, e.g. significant prior radiation exposure and pregnancy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Age 60-65 ApoE e4+

    Participants in this cohort are between the ages of 60-65 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.

    Radiation: Amyloid PET scan · Drug: Tau PET scan using MK-6240 · Behavioral: Neurocognitive testing · Other: MRI

  • Experimental
    Age 66-70 ApoE e4-

    Participants in this cohort are between the ages of 66-70 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.

    Radiation: Amyloid PET scan · Drug: Tau PET scan using MK-6240 · Behavioral: Neurocognitive testing · Other: MRI

  • Experimental
    Age 66-70 ApoE e4+

    Participants in this cohort are between the ages of 66-70 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.

    Radiation: Amyloid PET scan · Drug: Tau PET scan using MK-6240 · Behavioral: Neurocognitive testing · Other: MRI

  • Experimental
    Age 71-75 ApoE e4-

    Participants in this cohort are between the ages of 71-75 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.

    Radiation: Amyloid PET scan · Drug: Tau PET scan using MK-6240 · Behavioral: Neurocognitive testing · Other: MRI

  • Experimental
    Age 71-75 ApoE e4+

    Participants in this cohort are between the ages of 71-75 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.

    Radiation: Amyloid PET scan · Drug: Tau PET scan using MK-6240 · Behavioral: Neurocognitive testing · Other: MRI

  • Experimental
    Age 76-80 ApoE e4-

    Participants in this cohort are between the ages of 76-80 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.

    Radiation: Amyloid PET scan · Drug: Tau PET scan using MK-6240 · Behavioral: Neurocognitive testing · Other: MRI

  • Experimental
    Age 76-80 ApoE e4+

    Participants in this cohort are between the ages of 76-80 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.

    Radiation: Amyloid PET scan · Drug: Tau PET scan using MK-6240 · Behavioral: Neurocognitive testing · Other: MRI

  • Experimental
    Age 81+ ApoE e4-

    Participants in this cohort are between the ages of 81-85 and are not ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.

    Radiation: Amyloid PET scan · Drug: Tau PET scan using MK-6240 · Behavioral: Neurocognitive testing · Other: MRI

  • Experimental
    Age 81+ ApoE e4+

    Participants in this cohort are between the ages of 81-85 and are ApoE e4 carriers. All participants in this cohort will complete the Amyloid PET scan, Tau PET scan using MK-6240, MRI scans, and neurocognitive testing.

    Radiation: Amyloid PET scan · Drug: Tau PET scan using MK-6240 · Behavioral: Neurocognitive testing · Other: MRI

Interventions

  • RadiationAmyloid PET scan

    Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18

  • DrugTau PET scan using MK-6240

    Tau Positron Emission Tomography scan using radio tracer MK-6240

    Also known as: tau PET

  • BehavioralNeurocognitive testing

    A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.

  • OtherMRI

    High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.

06

What researchers measure

Primary outcomes

  1. Change in Clinical Dementia Rating - Sum of Box Score

    A measure of cognitive/clinical decline

    Time frame: Years 4 and 5 of the grant

Secondary outcomes

  1. Change in lure discrimination index - objects

    Key measure of performance on the object pattern separation task

    Time frame: Years 4 and 5 of the grant

  2. Change in lure discrimination index - spatial

    Key measure of performance on the spatial pattern separation task

    Time frame: Years 4 and 5 of the grant

  3. Change in lure discrimination index - temporal

    Key measure of performance on the temporal pattern separation task

    Time frame: Years 4 and 5 of the grant

  4. Change in entorhinal cortical thickness

    Key measure of structural decline on MRI scans

    Time frame: Years 4 and 5 of the grant

  5. Change in perforant path integrity

    Key measure of structural connectivity decline on MRI scans

    Time frame: Years 4 and 5 of the grant

  6. Change in tau spatial distribution - advancing Braak stage

    Key measure of tau spatial spread on tau PET scans

    Time frame: Years 4 and 5 of the grant

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Stevenson RF, Reagh ZM, Chun AP, Murray EA, Yassa MA. Pattern Separation and Source Memory Engage Distinct Hippocampal and Neocortical Regions during Retrieval. J Neurosci. 2020 Jan 22;40(4):843-851. doi: 10.1523/JNEUROSCI.0564-19.2019. Epub 2019 Nov 20. PubMed 31748377 ↗
  • Holbrook AJ, Tustison NJ, Marquez F, Roberts J, Yassa MA, Gillen DL; Alzheimer's Disease Neuroimaging Initiative section sign. Anterolateral entorhinal cortex thickness as a new biomarker for early detection of Alzheimer's disease. Alzheimers Dement (Amst). 2020 Aug 25;12(1):e12068. doi: 10.1002/dad2.12068. eCollection 2020. PubMed 32875052 ↗
  • Chappel-Farley MG, Mander BA, Neikrug AB, Stehli A, Nan B, Grill JD, Yassa MA, Benca RM. Symptoms of obstructive sleep apnea are associated with less frequent exercise and worse subjective cognitive function across adulthood. Sleep. 2022 Mar 14;45(3):zsab240. doi: 10.1093/sleep/zsab240. PubMed 34604910 ↗
  • Adams JN, Kim S, Rizvi B, Sathishkumar M, Taylor L, Harris AL, Mikhail A, Keator DB, McMillan L, Yassa MA. Entorhinal-Hippocampal Circuit Integrity Is Related to Mnemonic Discrimination and Amyloid-beta Pathology in Older Adults. J Neurosci. 2022 Nov 16;42(46):8742-8753. doi: 10.1523/JNEUROSCI.1165-22.2022. Epub 2022 Oct 27. PubMed 36302636 ↗
  • Adams JN, Marquez F, Larson MS, Janecek JT, Miranda BA, Noche JA, Taylor L, Hollearn MK, McMillan L, Keator DB, Head E, Rissman RA, Yassa MA. Differential involvement of hippocampal subfields in the relationship between Alzheimer's pathology and memory interference in older adults. Alzheimers Dement (Amst). 2023 Apr 5;15(2):e12419. doi: 10.1002/dad2.12419. eCollection 2023 Apr-Jun. PubMed 37035460 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2018 (actual). Primary completion is estimated for Dec 2026, 103 months after the start.

Of 101 phase 3 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 73. This study's planned 103 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2019
First posted
Mar 4, 2019
StartActual
May 1, 2018
Primary completionEst.
Dec 22, 2026
CompletionEst.
Dec 22, 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03860857
Responsible party
Michael Yassa (Professor, University of California, Irvine) — Principal investigator
First posted
Mar 4, 2019
Start date
May 1, 2018
Primary completion
Dec 22, 2026 (estimated)
Completion
Dec 22, 2027 (estimated)
Last update
Jan 23, 2026

Study contacts

Evelyn Chang, BA
Contact
beacon@uci.edu
949-824-0904
Novelle Meza, BS
Contact
njmeza@uci.edu
949-824-5049
Michael A Yassa, PhD
principal investigator · University of California, Irvine
Liv C McMillan, BS, CCRP
study director · University of California, Irvine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion